Affiliation:
1. University of Rochester
Publisher
American Society of Hematology
Reference9 articles.
1. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions;Handunnetti;Blood,2024
2. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma;Tam;N Engl J Med,2018
3. Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma;Agarwal;Nat Med,2019
4. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways;Zhao;Br J Haematol,2015
5. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 Sympatico Study [abstract];Wang;Blood,2023